DRB

DRB

CAT N°: 10010302
Price:

From 46.00 39.10

DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 µM){15211}, Cdk7 (IC50 = ~20 µM){15209,15207}, Cdk8 (IC50 = ~20 µM){15207}, and Cdk9 (IC50 = 3 µM).{15214} Through inhibition of certain CTD kinases, DRB inhibits an elongation step during RNA polymerase II transcription{15210,15208}, which can trigger p53-dependent apoptosis of human colon adenocarcinoma cells without inducing genotoxic stress to healthy cells.{15213} DRB can also inhibit HIV transcription (IC50 = ~4 µM) by targeting elongation enhanced by the HIV-encoded transactivator Tat.{15212}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 5,6-dichloro-1-?-D-ribofuranosyl-1H-benzimidazole
  • Correlated keywords
    • cancers HIV P53 apoptosis Cdk7 Cdk9 CTD CKI CKII adenosine inhibitors inhibits inhibition transcription RNA polymerase cell cycles adenocarcinoma transactivator tat
  • Product Overview:
    DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 µM){15211}, Cdk7 (IC50 = ~20 µM){15209,15207}, Cdk8 (IC50 = ~20 µM){15207}, and Cdk9 (IC50 = 3 µM).{15214} Through inhibition of certain CTD kinases, DRB inhibits an elongation step during RNA polymerase II transcription{15210,15208}, which can trigger p53-dependent apoptosis of human colon adenocarcinoma cells without inducing genotoxic stress to healthy cells.{15213} DRB can also inhibit HIV transcription (IC50 = ~4 µM) by targeting elongation enhanced by the HIV-encoded transactivator Tat.{15212}

We also advise you